Tiziana Life Sciences (TLSA) Share-based Compensation (2017 - 2025)
Tiziana Life Sciences (TLSA) posted quarterly Share-based Compensation of $8.2 million for Q2 2025, up 7.2% year-over-year from $7.7 million in Q2 2024, and up 8.16% quarter-over-quarter from $7.6 million in Q4 2024.
Tiziana Life Sciences (TLSA) Share-based Compensation (2017 - 2025) Analysis & Trends
Tiziana Life Sciences' Share-based Compensation history runs 8 years deep, the most recent figure standing at $8.2 million for Q2 2025.
- In Q2 2025, Share-based Compensation rose 7.2% year-over-year to $8.2 million; the TTM figure through Jun 2025 stood at $8.2 million (up 7.2% YoY), while the FY2025 annual figure was $1.9 million, down 74.46% from the prior year.
- Share-based Compensation for Q2 2025 stood at $8.2 million, up from $7.6 million in the prior quarter.
- The five-year high for Share-based Compensation was $13.8 million in Q4 2021, with the low at $5.2 million in Q4 2022.
- The 5-year median for Share-based Compensation is $7.7 million (2024), against an average of $8.7 million.
- The sharpest annual moves came in 2022 and 2023: Share-based Compensation slumped 62.38% in 2022, then jumped 33.04% in 2023.
- Tiziana Life Sciences' Share-based Compensation stood at $13.8 million in 2021, then plunged by 62.38% to $5.2 million in 2022, then surged by 33.04% to $6.9 million in 2023, then climbed by 10.44% to $7.6 million in 2024, then gained by 8.16% to $8.2 million in 2025.
- Business Quant data shows TLSA's Share-based Compensation at $8.2 million in Q2 2025, $7.6 million in Q4 2024, and $7.7 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.70 Bn | 131.85 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.74 Bn | 78.75 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.36 Bn | 60.18 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.15 Bn | 54.01 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.88 Bn | 28.57 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.59 Bn | 26.43 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.48 Bn | - | - |
| 10 | Tiziana Life Sciences | 133.66 Mn | 129.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 8.25 Mn |
| Jun 30, 2025 | 8.25 Mn |
| Dec 31, 2024 | 7.63 Mn |
| Dec 31, 2024 | 7.63 Mn |
| Jun 30, 2024 | 7.69 Mn |
| Jun 30, 2024 | 7.69 Mn |
| Dec 31, 2023 | 6.91 Mn |
| Dec 31, 2023 | 6.91 Mn |
| Jun 30, 2023 | 6.09 Mn |
| Jun 30, 2023 | 6.09 Mn |
| Dec 31, 2022 | 5.19 Mn |
| Dec 31, 2022 | 5.19 Mn |
| Jun 30, 2022 | 11.45 Mn |
| Jun 30, 2022 | 11.45 Mn |
| Dec 31, 2021 | 13.80 Mn |
| Dec 31, 2021 | 13.80 Mn |
| Jun 30, 2021 | 11.64 Mn |
| Jun 30, 2021 | 11.64 Mn |
| Dec 31, 2019 | 4.95 Mn |
| Dec 31, 2019 | 4.95 Mn |